- The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion recommending approval for an expanded label for Pfizer's (PFE -0.2%) Prevenar 13 to include the prevention of pneumonia in patients at least 18 years old caused by the 13 pneumococcal serotypes in the vaccine.
- Prevenar's current indication in Europe is for the prevention of invasive pneumococcal disease in the same population.
- A final decision from the European Commission usually takes ~60 days.